Compound Evidence File
#EC-2026-0417
KPV
Filed under Peptides. The bureau holds 144 laboratory returns for this compound from 50 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
50 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 10.0 | 10.0 | 13 Feb 2026 | 20 Jun 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 10.0 | 10.0 | 10.0 | 1 Dec 2025 | 1 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 10.0 | 9.9 | 10.0 | 8 Jan 2026 | 3 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 10.0 | 10.0 | 10.0 | 6 Apr 2026 | 11 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 10.0 | 9.9 | 10.0 | 12 Apr 2026 | 26 Jun 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 9.9 | 10.0 | 6 Jan 2026 | 25 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 10.0 | 9.9 | 10.0 | 20 Apr 2026 | 5 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 9.9 | 10.0 | 8 Jan 2026 | 3 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 8 Mar 2026 | 18 Jun 2026 |
| AsymchemCASE #VI-2026-0091 | A | 3 | 10.0 | 10.0 | 10.0 | 9 Jan 2026 | 12 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 10.0 | 10.0 | 10.0 | 17 Mar 2026 | 22 Mar 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 10.0 | 10.0 | 10.0 | 2 Jun 2026 | 27 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 10.0 | 3 Jun 2026 | 14 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 9.9 | 9.9 | 10.0 | 7 Mar 2026 | 5 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 9.9 | 9.9 | 10.0 | 23 Jan 2026 | 18 Aug 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 9.9 | 9.9 | 10.0 | 13 Jan 2026 | 6 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 2 | 9.9 | 9.9 | 10.0 | 4 Apr 2026 | 11 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 9.9 | 9.9 | 9.9 | 3 Mar 2026 | 22 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 2 | 9.9 | 9.9 | 10.0 | 11 Feb 2026 | 8 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 9.9 | 9.9 | 9.9 | 12 May 2026 | 17 May 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 2 | 9.9 | 9.9 | 10.0 | 8 Feb 2026 | 6 Apr 2026 |
| NUPEPS PeptidesCASE #VI-2026-0896 | X | 1 | 9.6 | 9.6 | 9.6 | 17 Dec 2024 | 17 Dec 2024 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 7 | 8.9 | 7.5 | 10.0 | 23 May 2026 | 23 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 8.9 | 8.3 | 9.5 | 21 May 2026 | 21 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 5 | 8.6 | 6.1 | 9.8 | 21 May 2026 | 21 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 6 | 8.5 | 6.7 | 9.3 | 23 May 2026 | 23 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 8.2 | 8.0 | 8.5 | 24 May 2026 | 24 May 2026 |
| Peptide PartnersCASE #VI-2026-0295 | X | 6 | 8.1 | 4.8 | 10.0 | 24 Apr 2025 | 19 Jan 2026 |
| Polaris PeptidesCASE #VI-2026-0839 | X | 6 | 7.5 | 6.1 | 9.4 | 28 Mar 2025 | 26 Jan 2026 |
| LiliPeptideCASE #VI-2026-0695 | X | 2 | 7.5 | 7.1 | 8.0 | 21 May 2025 | 19 Jan 2026 |
| Bio PepzCASE #VI-2026-0436 | X | 1 | 7.5 | 7.5 | 7.5 | 16 Mar 2025 | 16 Mar 2025 |
| Huaian Hanyou PeptideCASE #VI-2026-0297 | X | 1 | 7.4 | 7.4 | 7.4 | 13 Jun 2025 | 13 Jun 2025 |
| Allen Biotechnology Co ABCCASE #VI-2026-0709 | X | 3 | 6.9 | 5.9 | 8.3 | 8 Jul 2025 | 21 May 2026 |
| Accelerate LabsCASE #VI-2026-0686 | X | 2 | 6.9 | 6.8 | 7.0 | 11 Jun 2025 | 21 May 2026 |
| Verified PeptidesCASE #VI-2026-0407 | X | 3 | 6.7 | 5.7 | 8.2 | 27 Feb 2025 | 26 Jan 2026 |
| Xingruida XDRCASE #VI-2026-0898 | X | 1 | 6.4 | 6.4 | 6.4 | 8 Jul 2025 | 8 Jul 2025 |
| Huayi BiotechnologyCASE #VI-2026-0243 | X | 1 | 6.2 | 6.2 | 6.2 | 13 Feb 2025 | 13 Feb 2025 |
| Elite Research USACASE #VI-2026-0267 | X | 2 | 5.4 | 4.1 | 6.7 | 3 Jul 2025 | 26 Jan 2026 |
| YB PeptideCASE #VI-2026-0813 | X | 1 | 5.4 | 5.4 | 5.4 | 25 Apr 2025 | 25 Apr 2025 |
| Dankang BioHealthCASE #VI-2026-0775 | X | 1 | 5.0 | 5.0 | 5.0 | 9 Jun 2025 | 9 Jun 2025 |
| Amino AsylumCASE #VI-2026-0828 | X | 1 | 4.6 | 4.6 | 4.6 | 6 May 2025 | 6 May 2025 |
| Suaway Lab ResearchCASE #VI-2026-0488 | X | 2 | 4.3 | 3.6 | 5.0 | 27 Feb 2025 | 26 Jan 2026 |
| Xingtai Lesda TechnologyCASE #VI-2026-0381 | X | 1 | 4.0 | 4.0 | 4.0 | 20 Jun 2025 | 20 Jun 2025 |
| Guangzhou Yuao TradingCASE #VI-2026-0787 | X | 1 | 3.2 | 3.2 | 3.2 | 13 Feb 2025 | 13 Feb 2025 |
| HybiopeptidesCASE #VI-2026-0305 | X | 1 | 3.1 | 3.1 | 3.1 | 13 Feb 2025 | 13 Feb 2025 |
| Swiss ChemsCASE #VI-2026-0030 | X | 1 | 2.8 | 2.8 | 2.8 | 6 May 2025 | 6 May 2025 |
| Coffee and PeppersCASE #VI-2026-0274 | X | 1 | 1.6 | 1.6 | 1.6 | 8 Jul 2025 | 8 Jul 2025 |
| Hebei Chengtong TechnologyCASE #VI-2026-0520 | X | 1 | 1.4 | 1.4 | 1.4 | 7 May 2025 | 7 May 2025 |
Open any subject to view the batch-level evidence for KPV alone.